View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 21, 2020

Coronavirus company news summary – RedHill investigates second candidate against Covid-19 – EC sets up a European Covid-19 data database

By Allie Nawrat

21 April 2020 

Alexion Pharmaceuticals intends to launch a Phase III clinical trial to assess its drug Ultomiris (ravulizumab-cwvz) to treat Covid-19 patients hospitalised with severe pneumonia or acute respiratory distress syndrome (ARDS). The drug is a C5 inhibitor already approved to treat a range of diseases in the US and European Union.

A Covid-19 vaccine candidate developed by a research team at the University of Georgia (UGA) College of Veterinary Medicine has shown promise in test models. The vaccine consists of engineered strains of the parainfluenza virus 5 (PIV5), which is responsible for kennel cough in dogs. Read the full story here.

RedHill Biopharma has signed an agreement with the National Institute of Allergy and Infectious Diseases (NIAID) to offer its drug candidate RHB-107 (upamostat, WX-671) for non-clinical testing against Covid-19. RHB-107 is a serine protease inhibitor being developed as a cancer drug candidate; it is the second of RedHill’s candidates to be investigated against Covid-19.

India-based company Zydus Cadila is set to explore its biological therapy Pegylated Interferon alpha-2b, PegiHep, as potential treatment for Covid-19. The candidate has been selected based on two research articles, published on bioRxiv and medRxiv, which provide evidence of interferon alpha’s antiviral activity against the novel coronavirus in-vitro. Interferon alpha-2b has been used to treat Covid-19 in China and Cuba.

The European Commission, in alliance with various partners, has introduced the European COVID-19 Data Platform for quick collection and sharing of research data in order to speed-up research and discovery. The platform will allow researchers to store and share datasets, including DNA sequences, protein structures, pre-clinical research and clinical trials data, along with epidemiological data.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU